PharmaNet, a Princeton, N.J., clinical drug development company once under U.S. Senate investigation for its treatment of human test subjects, now faces an avalanche of shareholder litigation.
A putative class-action suit in federal court in Newark alleges the company and its top executives made false and misleading statements to investors, engaged in improper business practices and tried to cover them up.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
